

PRESS RELEASE

# Nippon Soda licenses MabGenesis' therapeutic antibodies for feline inflammatory diseases

**Yokohama, Japan, April 28, 2026** –Nippon Soda Co., Ltd. (“Nippon Soda”) announces that it has licensed novel therapeutic antibodies for feline inflammatory diseases from MabGenesis Inc. (“MabGenesis”), a private biopharmaceutical company headquartered in Yokohama, Japan.

Under the agreement, Nippon Soda has the right to develop and commercialize products using the therapeutic antibodies for potential treatments of feline inflammatory diseases. MabGenesis will receive an upfront payment and is entitled to receive milestone payments based on developmental progress as well as sales royalties.

Katsuhiko Shinjo, DVM, PhD, Chief Executive Officer of MabGenesis commented: "We are delighted to have the opportunity to license our fully feline monoclonal antibodies, generated through our proprietary antibody platform technology, to Nippon Soda. We are convinced that Nippon Soda's expertise and strong development capabilities will successfully translate this asset into safe and effective treatments for cats worldwide."

Makoto Kato, Executive Officer and General Manager of Chemical Products Division, Nippon Soda Co., Ltd. Commented:

"The animal health field, where we can leverage our chemical and biochemical knowledge cultivated through agrochemical research and development, represents an important area where we can utilize our strengths. Through our collaboration with MabGenesis, we aim to integrate their innovative technologies with our expertise to achieve early commercialization. MabGenesis's MOURA Library, which provides high-performance monoclonal antibodies that are difficult to obtain with conventional technologies, is innovative, and we will work together with MabGenesis to realize the practical application of veterinary monoclonal antibody therapeutics, utilizing our expertise cultivated over many years."

## **About MabGenesis Inc.**

MabGenesis is a startup biopharmaceutical company engaged in the research and development of therapeutic monoclonal antibody drugs. The company possesses the world's highest quality phage display antibody library (MOURA Library) and provides high-quality monoclonal antibodies that are difficult to obtain using conventional technologies. In September 2025, MabGenesis entered into a collaborative research agreement with Nippon Soda for the development of novel monoclonal antibody therapeutics for dogs and cats.

For more information, visit <https://mabgenesis.com/en> and connect with us on [LinkedIn](#).

## **MabGenesis Inc. press contact**

Yuichiro Shibazaki – Chief Business Officer

Email: [business@mabgenesis.com](mailto:business@mabgenesis.com)

Phone: +81 80 5926 4677

**About Nippon Soda Co., Ltd.**

The Company's mission is to create new value through the power of chemistry and increase corporate value by contributing to society. Under this mission, the Company will continue to pursue the creation of new businesses in the animal health field. Through this license acquisition, the Company will advance the development and commercialization of antibody therapeutics for cats, contributing to the resolution of social issues related to animal healthcare.

For more information, visit <https://www.nippon-soda.co.jp/e/>.

**Nippon Soda press contact**

Corporate Communication Sec. General Affairs Dept.

Email: [info@nissogr.com](mailto:info@nissogr.com)

---